Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies announced this week that it has signed agreements or received positive medical coverage decisions for its ClonoSeq Assay with several large national and regional health insurers in the US, bringing the total number of covered lives to more than 140 million. The agreements and medical policies expand access to ClonoSeq for minimal residual disease (MRD) testing in patients with lymphoid cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.